Automated Multiplex CRISPR-Cas13 Transcriptome Editing Foundry Cap Rate 2026

Underwrite GMP Class A/B continuous synthetic Cas13d high-efficiency RNA knockdown and ADAR-recruiting RNA base editing vector suites, $575/sqft base lease rates, and exit cap rates.

Underwriting Assumptions

Cas13 Cleanroom Footprint (sqft)

NNN Base Lease Rate ($/sqft/yr)

Turnkey GMP Cas13 Foundry Acquisition ($)

Target Exit Capitalization Rate (%)

Projected Economics

Net Operating Income (NOI)

Going-In Capitalization Rate

Stabilized Institutional Valuation